Composition for detecting the response of rectal adenocarcinomas to radiochemotherapy

US8852861B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Thomas Ried · Bethesda, US
• Michael J. Difilippantonio · Rockville, US
• Bijan-Michael Ghadimi · Bethesda, US
• Marian Grade · Oettingen, DE
• Heinz Becker · Oettingen, DE
• Torsten Liersch · Oettingen, DE

Key dates

• Filing date: Jan 12, 2005
• Grant date: Oct 7, 2014
• Expiry date: Aug 26, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/16
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

A cDNA array (9984 genes) was used for expression profiling in rectal adenocarcinoma. The expression data were correlated to responsiveness to chemotherapy followed by radiotherapy. A set of 54 genes was found that were differentially expressed in responders vs. non-responders. The genes may be used as prognostic markers for determining whether a rectal adenocarcinoma is responsive to radiochemotherapy.